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Objective: The study aimed determining whether assessment of cartilage oligomeric matrix protein
(COMP) degradation products could serve as a serological disease course and therapeutic response
predictor in arthritis.
Methods:We generated a panel of monoclonal antibodies against COMP fragments and developed a novel
capture enzyme-linked immunosorbent assay (ELISA) for detecting COMP fragments in patients with
osteoarthritis (OA) and rheumatoid arthritis (RA). This test was also used to monitor COMP fragments in
surgically-induced OA, collagen-induced arthritis (CIA), and tumor necrosis factor (TNF) transgenic
animal models.
Results: Compared with a commercial COMP ELISA kit that detected no signiﬁcant difference in COMP
levels between OA and control groups, a signiﬁcant increase of the COMP fragments were noted in the
serum of OA patients assayed by this newly established ELISA. In addition, serum COMP fragment levels
were well correlated with severity in OA patients and the progression of surgically-induced OA in murine
models. Furthermore, the serum levels of COMP fragments in RA patients, mice with CIA, and TNF
transgenic mice were signiﬁcantly higher when compared with their controls. Interestingly, treatment
with TNFa inhibitors and methotrexate led to a signiﬁcant decrease of serum COMP fragments in RA
patients. Additionally, administration of Atsttrin [Tang, et al., Science 2011;332(6028):478] also resulted
in a signiﬁcant reduction in COMP fragments in arthritis mice models.
Conclusion: A novel sandwich ELISA is capable of reproducibly measuring serum COMP fragments in both
arthritic patients and rodent arthritis models. This test also provides a valuable means to utilize serum
COMP fragments for monitoring the effects of interventions in arthritis.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved..
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Arthritis is a group of chronic diseases that is characterized by
the damage of joints and the inﬂammation of soft tissue around the
joints1. The impact of arthritic conditions is expected to grow
because of increased longevity of the population and increased
environmentally induced diseases2. The lack of effective non-
surgical treatment modalities for arthritis may probably be attrib-
uted to late detection of disease, in particular late detection of
cartilage degeneration, at which point the patient’s chondrocytes
are no longer effective in stopping or reversing joint destruction3e5.
Thus, tremendous efforts have been taken to identify a speciﬁc
biological marker, which can help to make an early diagnosis ofublished by Elsevier Ltd. All rights reserved.
Table II
Demographic characteristic of RA cohort study






Drug naïve 61 47 (18e73) 51/10 5.56 (1.88e7.85) N/A
TNF-inhibitor 33 51 (25e79) 31/2 5.60 (1.67e8.40) 5.04 (1.54e7.88)
MTX 18 45 (18e65) 12/6 5.36 (3.62e7.82) 3.95 (2.02e6.37)
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sion, and to monitor the effects of drug treatment.
Cartilage oligomeric matrix protein (COMP), a prominent non-
collagenous component of cartilage, accounts for approximately 1%
of the wet weight of articular tissue6,7. Proteolytic fragments of COMP
have been detected in the degenerating cartilage, synovial ﬂuid, and
serum of patients with knee injuries, post-traumatic and primary OA
or RA8e10. COMP is a putative substrate formatrixmetalloproteinases
(MMPs), including MMP111, MMP1312, MMPs 19 and 2013, A Dis-
integrin And Metalloproteinase with Thrombospondin Motifs
(ADAMTS)-411, -714, and -1215. Increased fragments of COMP have
been reported inpatientswithOA, RA, and joint injury16e18, and show
great potential to serve as valuable biological markers of cartilage
breakdown inarthritis10,19,20.Hereinwe reportanovelCOMPenzyme-
linked immunosorbent assay (ELISA) for measuring the levels of
proteolytic COMP fragments in serum, and exploit the possibility of
employing COMP fragments as a biomarker for monitoring the
arthritic progression and the effects of therapeutic interventions.
Materials and methods
Human serum samples
Osteoarthritis (OA) Cohort: Patients with OA were recruited as
part of a NIH-funded study and 57 serum samples from these
patients were available for this study. All patients had symptomatic
knee OA according to the ACR criteria21. Twenty-one age-matched
healthy control subjects were also recruited. In all patients, radio-
graphs of the knee were obtained in lateral and antero-posterior
planes and the radiographic ﬁndings were scored according to
the Kellgren&Lawrence (K&L) scale22. Table I describes the demo-
graphic and clinical characteristics of OA and healthy controls.
RheumatoidArthritis (RA)Cohort: Samples frompatients affected
by RA, who met the ACR criteria23, were collected at the Depart-
mental Tissue Bank of the Division of Rheumatology. Patients were
evaluated using the Disease Activity Score including a 28 joint count
(DAS28)24. We selected serum samples from sixty-one RA patients
that were not prescribed any disease-modifying anti-rheumatic
drugs (DMARDs) at the time of blood collection. In addition, sera
from RA patients at baseline and after 3 or 5months treatment were
also collected, thirty-three pairs of samples from RA patients treated
with tumor necrosis factor (TNF) inhibitors (etanercept, inﬂiximabor
adalimumab) and eighteenpairs of samples fromRApatients treated
withmethotrexate (MTX)wereobtainedandstoredat80C. Table II
describes the demographic and clinical characteristics of RApatients.
All patient sampleswere approved for use in this studyby theHuman
Research Ethics Board of New York University Medical Center.
Construction of the expression plasmids encoding His-tagged
human and mouse COMP type III domain
The DNA fragment encoding human COMP type III domain was
generated by three cycles of polymerase chain reaction (PCR) using
a set of primers: forward primer P1 (50-gcgcgtccggacgcga-
cactgacctagac-30), forward primer P2 (50-gcgttcttctgctcaccctggctg
ccctcggcgcgtccggacgcga-30), forward primer P3 (50-aggatccac-
tatggtccccgacaccgcctgcgttcttctgctcacc-30), reverse primer (50-actc-
gaggagcgtgacttcagcgttc-30). For the mouse COMP type III domainTable I
Demographic characteristic of OA cohort study




Controls 21 51 (31e67) 12/9 21.4 (19.1e24.7) 14/5/2
OA 57 64 (39e81) 39/18 26.8 (15.4e32.6) 24/19/14construct, mouse cDNA was used as template and the following
primers were used: forward primer P1 (50-gggcgacaggccgcga
cacggacctgga-30), forward primer P2 (50-gcgttctagtgctcgccctggc
tatcctgc gggcgacaggccgcga-30), forward primer P3 (50-aggatc
catgggccccactgcctgcgttctagtgctcgcc-30), reverse primer (50-
cctcgagctcggggcacacatcgatct-30). BamH I and Xho I sites are
underlined and the italic letters represent three parts of the signal
peptide sequence of COMP. After three cycles, these sequences were
joined together to generate the intact N-terminal signal peptide,
which facilitated the recombinant protein secretion into the culture
medium. The ampliﬁed DNA fragment was ligated into the BamH I
and Xho I sites of pCDNA3.1-myc-his A (Invitrogen).
Expression and puriﬁcation of recombinant COMP type III in HEK
293EBNA cells
HEK 293EBNA cells were transfected with 20 mg DNA using Lip-
ofectamine 2000 (Invitrogen). The stable lines were generated by
G418 (Sigma) selection. The serum-free conditioned medium was
mixedwithProbondNickel-ChelatingResin (Invitrogen). Thebound
proteins in thewashed resinwere elutedwith 250mM Imidazole. The
secretion of recombinant protein was conﬁrmed by SDS-PAGE. Addi-
tionally, the recombinant proteinswere analyzed byWestern blotting
using a rabbit anti-COMP polyclonal antiserum (pAb) or anti-COMP
type III monoclonal antibody (mAb) 2127F5, respectively.
Generation and partial characterization of mAbs against the COMP
type III domain
Female Balb/c mice were immunized with the recombinant type
III domain of COMP (aa 266e526) and hybridomas were produced
according to standard procedures. Procedures for spleen fusion and
clone selection were as previously described25.
Recombinant human COMP was incubated with MMP13 cata-
lytic domain (Abcam) or puriﬁed catalytic domain of ADAMTS-7 in
digestion buffer (50mMTriseHCl,100mMNaCl, 5 mMCaCl2, 2 mM
ZnCl2, and 0.05% Brij-35, pH 7.5, substrate and enzyme molar ratio
6:1) at 37C for 16 h. The digested products were analyzed by
Western blotting using selected mAbs or the pAb against COMP.
Epitope mapping of anti-COMP mAb 2127F5
An overlapping peptide library for human COMP type III domain
was designed and generated by Genscript Inc (Piscataway, New
Jersey). Each peptide of the library was 15 amino acid long with 10
amino acids overlapping with its adjacent peptide. All cysteines in
the peptides were replaced with serine. A total of 51 biotinylated
overlapping peptides were synthesized and screened by ELISAwith
mAb 2127F5.
Immunoblotting for COMP in serum
A volume of 10 ml of hyaluronidase (100 U in 0.05 M sodium
acetate buffer, pH 5.8) from bovine testis (Sigma) was added to
50 ml of serum from normal control, OA patients, and RA patients.
After incubation at 37C for 2 h, samples were precipitated by
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serum, and incubated on ice for 20 min. The supernatant was spun
and the pellet washed ﬁrst with ice-cold acetone twice and then
dissolved in non-reducing SDS-PAGE loading buffer. Soluble
material was subjected to SDS-PAGE and detected with either the
anti-COMP pAb or mAb 2127F5.
Immunohistochemistry
Specimens of articular cartilage from OA and RA patients and
normal controls were ﬁxed in 4% PBS buffered PFA at 4C overnight
and then decalciﬁed in 10% EDTA for 4 weeks. After blocking, tissue
sections were incubated with mAb 2127F5 at 4C overnight, fol-
lowed by incubation with a biotinylated secondary anti-mouse IgG
for 1 h at room temperature. Following intermittent rinses in PBS,
avidin-biotin-peroxidase complex (Vector Elite ABC Kit; Vectastain)
was applied for 1 h and signal detection was performed by using
diaminobenzidine for 10 min (SigmaeAldrich) as the substrate,
followed by a counterstaining with methyl green.
Sandwich ELISA
Brieﬂy, the anti-COMP pAb26 was used as a capture antibody,
whereas mAb 2127F5 was used as a detection antibody. Ninety-six
well ELISA plates were coated with 50 ml/well of anti-COMP pAb
diluted with PBS to 2 mg/ml and kept overnight at 4C. Coated wells
were washed with PBST (PBS with 0.5% Tween-20) and blocked
with 5% BSA (w/v) in PBS for 1.5 h at room temperature. Human or
mouse type III standards (6.25, 12.5, 25, 50, 100 ng/ml) and serum
samples (1/50 dilution for human, 1/10 for mouse) diluted with
0.5% BSA in PBST were transferred to BSA pre-saturated wells at
100 ml/well and incubated for 2 h at room temperature. Plates were
washed with PBST and 100 ml of diluted HRP conjugated detection
antibody (diluted to 1 mg/ml with 0.5% BSA in PBST) was added. The
plates were incubated for 2 h at room temperature and washed
with PBST. Peroxidase substrate TMB solution (eBioscience) was
applied to plates at 100 ml/well. The plates were incubated for
20 min and color development stopped by 100 ml 2 M sulfuric acid.
The COMP concentrations in the serum were calculated from the
linear range of a standard curve. To determine intra- and inter-
assay variance, six fresh aliquots of one serum sample on each
plate were stored at 80C. Each day a plate was thawed and
measured with six repeats on one plate for six consecutive plates.
For comparison, serum COMP levels of twenty-one normal
controls andﬁfty-sevenOApatientsweremeasuredbyCOMPHuman
ELISA kit (BioVendor) according to the manufacturer’s protocol.
Arthritis animal models
An instability-induced OA model was created in 8-week-old
C57BL/6 mice. The animals were anesthetized and the right knee
joint was destabilized by transection of the medial meniscotibial
ligament followed by removal of the cranial half of the medial
meniscus. Control mice were sham-operated using the same
approach but without any ligament transection or meniscectomy.
Mice were kept for an additional 12 weeks after surgery.
For generation of a collagen-induced arthritis (CIA) model, 8-
week-old male DBA1/J mice were immunized via a 0.1 ml intra-
dermal injection at the base of the tail with 100 mg chicken type II
collagen (Chondrex) emulsiﬁed with an equal volume of complete
Freund’s adjuvant (Chondrex). Four weeks after the ﬁrst immuni-
zation, 2.5 mg/kg etanercept, rhPGRN, or Atsttrin antagonist of TNF/
TNRF signaling via targeting to TNF receptors were administered
intraperitoneally twice every week, and the COMP fragment levels
were measured by ELISA 4 weeks after treatment.TNF-Tg mice with mild (clinical score 4e6) arthritis were
administered intraperitoneal PBS or Atsttrin (2.5 mg/kg body
weight) twiceperweek. Theclinical score andserumCOMPfragment
levels were determined every week post-treatment for 4 weeks.
All animal studies were performed in compliance with the
Institutional Animal Care and Use Committee approved protocols.
Statistical analysis
The non-parametric ManneWhitney test (two-tailed) was used
to compare COMP serum levels in two unpaired groups, and the
Wilcoxon’s matched pairs test (two-tailed) was used to compare
the results of baseline and end COMP levels in individual patients.
Correlations were assessed using the Spearman’s correlation coef-
ﬁcient. Associations between continuous and qualitative variables
were evaluated by the analysis of variance (ANOVA). All P values
were two sided, and the P value <0.05 was considered to be
statistically signiﬁcant. All statistics were carried out using SPSS
version 11.0 (SPSS Inc., Chicago, IL).
Results
mAb 2127F5 recognizes degradation fragments of COMP present in
serum of arthritic patients
An immunoblotting screeningwas performed in order to identify
mAbs that might preferentially recognize degradation products of
COMP. As shown in the panel “a” of Fig. 1(A), ten of selected anti-
COMP mAbs recognized intact human COMP, while mAb 2127F5
exhibited lower reactivity toward intact COMP; however this mAb
showed enhanced reactivity against fragmented COMP produced by
in vitro digestionwith eitherMMP13 [Fig.1(A), panel b] or ADAMTS-
7 [Fig. 1(A), panel c]. mAb 2127F5 was then selected for detection of
COMP fragments in the serum of patients with arthritis [Fig. 1(B)].
The major immunoactive COMP fragments recognized by mAb
2127F5 had apparent molecular weights (Mrs) ranging from 97 kDa
to 117 kDa, whereas the anti-COMP pAb recognized a broad range of
COMP polypeptides ranging from intact pentamers (>500 kDa) to
degraded lower molecular weight fragments. Immunohistochem-
istry carried out on human normal, OA, and RA articular cartilage
[Fig. 1(C)] revealed that COMP was enriched in the peri-cellular
matrices through the whole middle zone of normal cartilage,
while it exhibited a substantially different expression and distribu-
tion pattern in arthritic cartilage. COMP fragments were heavily
immunolocalized and showed the most abundant deposition in the
superﬁcial zone of OA cartilage. Accumulation of COMP fragments
was seen in both the superﬁcial and middle zones of RA cartilage.
Peptide-based mapping of using a purposely designed peptide
library (Supplementary Data) pinpointed the epitope sequence
recognized by mAb 2127F5 at amino acids 483e497
(NCRLVPNPGQEDADR) of COMP [Fig. 1(D)].
Sandwich ELISA based upon mAb 2127F5 reveals a signiﬁcant
increase of COMP degradation products in the serum of OA and RA
patients
In order to develop an ELISA procedure for speciﬁc assessments
of circulating COMP fragments, we generated expression plasmids
encoding the human and mouse type III domain of COMP. Puriﬁed
type III domains were examined by SDS-PAGE [Fig. 2(A)] and were
conﬁrmed to exhibit an apparent Mr of 55 kDa, which was much
higher than the predicted Mr of 29 kDa and may presumably be
associated with post-translational modiﬁcations characterizing
COMP6,27. In addition, identity of these recombinant type III
proteins was further veriﬁed by Western blotting using both the
Fig. 1. Characteristics of the anti-COMP type III monoclonal antibody, mAb 2127F5. (A) Characterization of the COMP monoclonal antibodies using in vitro digestion assay. Intact
COMP (a), or digested with either MMP13 catalytic domain (b) or ADAMTS-7 catalytic domain (c), was resolved in 10% non-reduced SDS-PAGE and detected with a panel of
antibodies against COMP (1, rabbit pAb; 2e11, mAb: HC487E10H6, HCR6G5E12, HC644A8, HC8H7, HC490H10C8, H483A10G11, 2111A6, 2117B2, 2130E2, 2127F5). Arrow heads
represent the intact COMP, arrows indicate the digestive fragments. (B) Determination of the efﬁcacy of mAB 21275 in the detection of COMP fragments by Western blotting. The
serum samples from three each healthy donors, OA, and RA patients were ﬁrst digested by hyaluronidase and precipitated by TCA. They were then resolved in a 4e15% non-reducing
gradient gel, and visualized by immunoassay using rabbit anti-COMP pAb or anti-COMP type III mAb 2127F5. Arrows indicate the full length COMP and braces indicate degraded
COMP fragments. (C) Histological and immunostaining assay for COMP of normal, OA, and RA cartilage. The cartilage specimens were assayed using Safranin O-fast green staining,
and the immunohistochemistry for COMP using the mAb2127F5B6. Representative pictures are shown and black arrows indicate the expression of COMP in the cartilage. Scale
bars ¼ 100 mm. (D) Epitope mapping of the mAb 2127F5. Fifty-one peptides were synthesized and tested by ELISA using 2127F5, No. 44 peptide showed the positive signal, No. 52
and No. 53 were positive control and negative control respectively (For each library peptide reaction to mAb 2127F5, see Supplementary Data).
Y. Lai et al. / Osteoarthritis and Cartilage 20 (2012) 854e862 857anti-COMP pAb and mAb 2127F5 [Fig. 2(B)]. A sandwich ELISA was
then devised using the recombinant COMP type III fragments as
a standard. A representative typical standard curve is shown in
Fig. 2(C), having a linear range of 10e100 ng/ml. The overall intra-
assay and inter-assay coefﬁcients of variation were estimated to be
7.2% and 8.7%, respectively. To validate our ELISA protocol, serum
COMP levels from 57 patients diagnosed with OA and 21 healthy
controls were comparatively measured with our assay and
a commercial COMP ELISA kit. While the latter did not detect
signiﬁcant differences in COMP levels between symptomatic kneeOA (OA) and non-OA control groups (P ¼ 0.128), a signiﬁcant
increase of the COMP fragments was noted in the serum of OA
patients assayed with our ELISA setting (P ¼ 0.005) [Fig. 3(A)]. In
addition to OA, the COMP serum level in RA patients measuredwith
our sandwich ELISA was signiﬁcantly higher compared with
healthy controls [2390 ng/ml (95CI: 2124.7e2655.3 ng/ml) vs
153.5 ng/ml (95CI: 120.5e188.9 ng/ml), P < 0.0001; Fig. 3(C)].
According to these data, the sensitivity of this newly established
ELISA protocol for distinguishing RA from healthy individuals was
87.72%, while the speciﬁcity of the assay could reach to 100%.
Fig. 2. Characterization of recombinant COMP type III domain and the establishment of the sandwich ELISA using recombinant COMP type III as a standard. (A) The
HEK293-EBNA cells were transfected with either expression plasmid encoding His-tagged human COMP type III (lane 1), His-tagged mouse COMP type III (lane 3), or empty vector
as a control (lane 2) and the conditioned media collected. Puriﬁed recombinant proteins using Ni-NTA resin were separated by non-reducing 10% SDS-PAGE gel and visualized with
Coomassie Brilliant blue staining. (B) After puriﬁcation with Ni-NTA resin, the expression of recombinant human COMP type III (lane 1) and mouse COMP type III (lane 3) was
veriﬁed by Western blot using anti-COMP pAb (a) or anti-COMP mAb 2127F5 (b). No band was detected in the control media (lane 2). (C) The standard curve was generated by the
serial concentration of diluted recombinant human COMP type III plotted against the OD450 value; the blank has been subtracted from all the absorbances.
Y. Lai et al. / Osteoarthritis and Cartilage 20 (2012) 854e862858Serum levels of COMP fragments correlate with the K&L grade score
in OA patients and with the progression of surgically-induced OA in
murine models
To better explore the potential of COMP as a biomarker of clin-
ical utility, OA patients were divided into ﬁve groups according to
the radiological changes of their joints using the K&L grading scale
and the serum COMP levels were assessed with our ELISA protocol.
As shown in Fig. 3(B), patients with higher K&L grades also dis-
played signiﬁcantly higher serum COMP levels. Importantly, our
COMP ELISA was also able to detect murine COMP fragments in
operated mice showing gradual articular cartilage loss due to the
instability of the knee joint. In these mice, the change in histology
was indicated by the modiﬁed Mankin Score [Fig. 4(A)], while
sham-operated mice remained unaffected. In these mice OA
models, the serum COMP levels were determined at different time
points after surgery; the experimental group showed signiﬁcantly
higher levels of COMP at 8 and 12 weeks post-surgery compared
with the control, while COMP levels remain unchanged in sham-
operated mice [Fig. 4(B)].Fig. 3. COMP fragment levels were gradually elevated in the progression of both huma
controls using both the commercial ELISA kit and the newly established sandwich ELISA. Th
horizontal band in the box represents the median value, the ends of the whiskers represent
the normal group. (B) Adjusted serum COMP levels (ln scale) were correlated with the K&L g
group (n ¼ 31); K&L grade 2 group (n ¼ 29); grade 3 group (n ¼ 35); and K&L grade 4 group
values between 2.5th and 97.5th percentile, the horizontal band in the box represents the
0 group, ANOVA followed by post-hoc Dunnett’s multiple comparison test. (C) Serum COMP
(n ¼ 21). ***P < 0.001. The COMP levels increased in the progression of OA in the mice model
joints harvested 4, 8, and 12 weeks after surgery (n ¼ 6e8 mice per group). Articular cartila
determined pre-surgery and 4 weeks, 8 weeks, and 12 weeks after surgery. Sham-operated
when compared with sham group at matched time point.Alterations in serum levels of COMP fragments in mice with CIA, and
TNF-a transgenic mice
The CIA mouse model28,29 shares both immunological and
pathological features with human RA and we therefore analyzed in
a similar manner COMP levels in the CIA model. As indicated in
Fig. 4(C), signiﬁcantly increased COMP levels were observed in the
CIA group compared to the PBS control group at 4 weeks after the
ﬁrst immunization. TNF-Tg mice are known to develop an inﬂam-
matory arthritis phenotype spontaneously30,31. COMP fragment
levels were also signiﬁcantly higher in those mice compared with
the wild type control mice [Fig. 4(D)].
Treatments with TNFa inhibitors and MTX lead to a signiﬁcant
decrease of COMP fragmentation detected in the blood of RA
patients
In order to determine whether alterations in the serum COMP
level can be used for monitoring the efﬁcacy of therapeutic agents
administered to RA patients, a total of 33 RA patients who weren OA and RA. (A) Measurements of serum COMP levels from OA patients and normal
e bottom and top of the box indicating values between 2.5th and 97.5th percentile, the
10th and 90th percentile, respectively. The P value was calculated when compared with
rade score in OA patients and normal controls: K&L grade 0 group (n ¼ 21); K&L grade 1
(n ¼ 32). The whiskers indicate the minimum and maximum values, the box indicating
median value, *P ¼ 0.046, **P ¼ 0.009, ***P < 0.001 when compared with K&L grade
level was markedly higher in RA patients (n ¼ 60) compared with the normal control
. Surgical OAwas induced in wild-type C57BL/6 mice at the age of 8 weeks and the knee
ge loss was evaluated by the modiﬁed Mankin Score, and the serum COMP levels were
mice were used as control. Error bars show 95% Conﬁdence Interval (CI), ***P < 0.001
Fig. 4. COMP fragment levels were signiﬁcantly increased in mouse surgically-induced OA model, the mouse CIA model, and TNFa transgenic mice. (A, B) The COMP levels
increased in the progression of OA in the mice model. Surgical OA was induced in wild-type C57BL/6 mice at the age of 8 weeks and the knee joints harvested 4, 8, and 12 weeks
after surgery (n ¼ 6e8 mice per group). Articular cartilage loss was evaluated by the modiﬁed Mankin Score, and the serum COMP levels were determined pre-surgery and 4 weeks,
8 weeks, and 12 weeks after surgery. Sham-operated mice were used as control, **P < 0.01, ***P < 0.001 when compared with sham group at matched time point. (C) Eight-week-
old DBA1/J mice were immunized with chicken collagen II to induce inﬂammatory arthritis, and serum COMP was measured in CIA and PBS control groups 15 weeks after primary
immunization (n ¼ 9). (D) TNFa transgenic mice spontaneously started to develop inﬂammatory arthritis at the age of 14 weeks. The serum was harvested and the COMP level was
determined. n ¼ 7 for each group, Error bars show 95% CI, ***P < 0.001.
Y. Lai et al. / Osteoarthritis and Cartilage 20 (2012) 854e862 859treated with TNFa inhibitors were examined for their serum
levels of COMP. All the RA patients in the follow-up study were
divided into two groups: responders and non-responders
according to European League Against Rheumatism (EULAR)
DAS28 response criteria24. Nineteen responders showed signiﬁ-
cant reduction in COMP levels [Fig. 5(A) panel a, P ¼ 0.0004],
while in the non-responders group (n ¼ 14) no signiﬁcant
difference of COMP levels was detected [Fig. 5(A) panel b]. Ten RA
patients classiﬁed as responders treated with MTX for a period of
5 months exhibited a signiﬁcant reduction in COMP levels
compared with the baseline level [Fig. 5(B) panel a, P ¼ 0.008]
and no signiﬁcant change of COMP levels was seen in non-
responders [n ¼ 8, Fig. 5(B), panel b]. In addition, the basal
levels of COMP fragments in responders were signiﬁcantly higher
than those in non-responders [Fig. 5(A and B) panel c, P ¼ 0.038
and 0.036 respectively].Fig. 5. The serum COMP fragment levels at baseline and post-treatment with TNFa inhib
inhibitors (TNFi) (n ¼ 33); after 12 weeks of treatment, patients were divided into responde
the baseline level (panel a, b, P ¼ 0.0004 and 0.884 respectively). The serum COMP levels at b
treated with MTX (n ¼ 18) for 5 months, serum COMP levels were compared with the baselin
COMP levels at baseline between the two groups were compared (panel c, P ¼ 0.036). ErroAdministration of progranulin (PGRN) and its derived Atsttrin also
signiﬁcantly reduces serum levels of COMP fragments in
inﬂammatory arthritis mice models
We recently reported that the growth factor PGRN binds to TNF
receptors and is therapeutic against inﬂammatory arthritis32.
Importantly, Atsttrin, an engineered protein composed of three
PGRN fragments, potently prevents inﬂammation in multiple
arthritis mouse models32. We then sought to determine whether
the treatment efﬁcacy of Atsttrin also correlated to the levels of
COMP fragments. Mice with CIA were treated with etanercept,
recombinant human PGRN (rhPGRN), Atsttrin, or PBS as a control,
and COMP levels were measured 4 weeks after treatment. As
shown in Fig. 6(A), the three treatment groups showed markedly
reduced COMP levels compared with the PBS group. We also used
TNFa transgenic mice that spontaneously develop inﬂammatoryitors and MTX in RA patients. (A) Patients diagnosed with RA were treated with TNFa
rs and non-responders group, each individual’s serum COMP level was compared with
aseline between the two groups were compared (panel c, P ¼ 0.038). (B) For RA patients
e level and the treatment end (panel a, b, P ¼ 0.008 and 0.782 respectively). The serum
r bars show 95% CI.
Fig. 6. Mice with established inﬂammatory arthritis were treated with PGRN or its derived protein Atsttrin. (A) Mice with CIA were treated with 2.5 mg/kg of etanercept,
rhPGRN, or Atsttrin twice a week, and the COMP fragment levels were measured by ELISA 4 weeks after treatment, ***P < 0.0001 versus the control PBS group. (B & C) TNFa
transgenic mice with a clinical score between 4 and 6 were treated with 2.5mg/kg body weight of Atsttrin, twice a week. The clinical score (B) and COMP fragment levels (C) were
determined every week post treatment for 4 weeks. n ¼ 6 each group, Error bars show 95% Conﬁdence Interval, *P < 0.05, **P < 0.01, ***P < 0.001 versus the control PBS group.
Y. Lai et al. / Osteoarthritis and Cartilage 20 (2012) 854e862860arthritis. TNFa transgenic mice at a clinical score between 4 and 6
were treated with Atsttrin, and COMP fragment levels were
determined every week post-treatment for 4 weeks. The PBS group
showed increasingly severe inﬂammation as indicated by clinical
score, while inﬂammation in the Atsttrin-treated group was
reversed [Fig. 6(B)]. COMP levels gradually decreased along with
the administration of Atsttrin, while the PBS group showed
signiﬁcantly increasing levels of COMP [Fig. 6(C)].
Discussion
COMP shows great promise as a biological marker of cartilage
metabolism in arthritis10,33 and increased fragmentation of COMP
has been reported in patients with arthritis and joint injury9,19. The
monitoring of COMP levels in synovial ﬂuid or serum has been
suggested to be a helpful method for assessing the presence and
progression of arthritis. Signiﬁcant efforts have therefore been
undertaken to design sensitive and highly speciﬁc serological
procedures for the measurements of COMP released into synovial
ﬂuid or serum. Numerous antibodies against COMP have been
generated and different ELISA protocols for assessing body ﬂuid
levels of COMP have been described during the years and in many
cases made commercially available. pAbs and mAbs used in those
assays were in most cases raised against intact COMP9,19 and were
suboptimal since they apparently exhibit a low afﬁnity for
proteolytic fragments of COMP, or entirely fail to recognize epitopes
within critically important regions of the COMP molecule prone to
degradation during cartilage destruction. We thus generated
a unique panel of anti-COMP mAbs by immunizing mice with
recombinant fragments corresponding to distinct COMP domains.
One suchmAb, denoted 2127F5 and directed against the COMP type
III domain, was found to show higher afﬁnity against a COMP
fragment found in human serum and containing this domain than
against the intact molecule. We then took advantage of this unique
reactivity and utilized this immunological reagent to develop
a novel assay to quantify proteolytic fragments of COMP circulating
in body ﬂuids. Epitope mapping of this mAb showed it recognized
a 15 amino acid-long sequence within the type III domain of COMP.
Although intact COMP also contains this epitope, it is plausible that
the mAb may more readily access its epitope in fragmented COMP
because of a possible unfolding of the epitope upon degradation of
the pentameric COMP molecule or due to conformation changes of
proteolytic fragments (Fig. 1). A more profound understanding of
the modes of binding and antigen afﬁnity modulation of mAb
2127F5 remains to be acquired bymore detailed proteomic analysis
of the protein region containing its epitope. In addition, whether
serum peptides and proteins not yet detected may bind to thisantibody and inﬂuence the assay signal in a yet undetermined way
remains to be delineated.
The majority of COMP released into the serum of healthy people
is in the intact form, while catabolism of COMP is signiﬁcantly
increased in patients with either OA or RA. We ﬁnd no signiﬁcant
difference between serum COMP levels in OA using a COMP
detection kit from BioVendor (Karasek, Czech Republic), whereas
previous reports using the same antibody pair as that composing
the BioVendor kit revealed that serum COMP levels were increased
in OA patients and correlated with the OA progression34,35, as well
as that higher baseline levels of COMP correlated with incident
OA36. This discrepancy may be due to the limited sample size of the
study or to a different compositions of the examined patient
cohorts34. The COMP ELISA protocol developed here reveals
a signiﬁcant difference in serum COMP levels between arthritic
patients and non-arthritic control subjects (Fig. 3). In addition, the
serum levels of COMP were even higher in patients with RA than
those with OA (Fig. 3), which probably resulted from the different
degree and pattern of articular cartilage degradation by various
inﬂammatory cytokines and proteolytic enzymes operating in the
pathogenesis of OA and RA.
Using our method, we found a signiﬁcant correlation between
levels of serum COMP fragments and the K&L grade (Fig. 3).
Western Ontario and McMaster Universities (WOMAC) Osteoar-
thritis Index, which quantiﬁes the pain, stiffness, and limitation of
function in OA patients, is another frequently used scoring system.
However, no signiﬁcant correlation between the serum COMP
levels and the WOMAC score was observed. This is probably due to
the fact that the WOMAC score only reﬂects the degree of symp-
toms, which not necessarily correlates with the degree of degen-
eration of the articular cartilage. Our ﬁndings suggest that the
serum levels of COMP fragmentation are a direct indicator of
cartilage degradation in OA and that this novel sandwich COMP
ELISA has the full potential for being employed as an accurate and
reproducible test for the clinical evaluation of OA patients. It is
worthwhile to note that this approach can also be used for
detecting the COMP fragment level in the mouse models of
surgically-induced OA, collagen-induced RA, and TNF transgenic
inﬂammatory arthritis (Figs. 4 and 6), while most available ELISA
kits only work for certain species. Thus, this provides another level
of utility of the assay which, accordingly, can be exploited for basic
and applied research on arthritis, especially that involving drug
development.
MTX has been a traditional, standard DMARD for patients who
have moderate to severe RA. New generation biological drugs,
which are represented by TNFa inhibitors, such as etanercept,
inﬂiximab, and adalimumab, have been recently adopted as the
Y. Lai et al. / Osteoarthritis and Cartilage 20 (2012) 854e862 861more effective anti-inﬂammatory therapeutics for treatment of
arthritis37. Efﬁcacious use of conventional and novel anti-TNF drugs
in RA therapy strongly relies upon the identiﬁcation of precise
prognostic factors capable of predicting the disease course of RA
and monitor the therapeutic response of patients undergoing such
therapeutic treatments. In this study, we found that 39% and 53%,
respectively, of the patients treated with MTX and anti-TNF drugs
showed a signiﬁcant reduction in COMP fragment levels (Fig. 5).
These ﬁndings were in accordance with a recent report revealing
that COMP level in RA decreases after therapy with TNF inhibi-
tors38. In addition, the higher serum levels of COMP fragments at
the baseline indicated the good response to treatment, suggesting
that serum abundance of COMP fragments can be a useful indicator
for the evaluation of the disease progression and in monitoring the
therapeutic response at an early stage in RA treatment. They may
therefore be valuable in the stratiﬁcation of arthritic patients
according to treatment-independent disease progression and
responsiveness to treatment and, hence, assist the clinician in the
choice of more individualized treatment protocols. This notion is in
part supported by the reported higher COMP levels detected in sera
predicted responders to TNF inhibition therapy39. Interestingly,
Atsttrin, an engineered protein derived from PGRN growth factor
and known to have potent anti-inﬂammatory activity in mice32,
also effectively inhibited the speciﬁc COMP degradation measured
with our ELISA protocol in the course of inﬂammatory arthritis in
mice (Fig. 6). The full clinical utility of our immune-serological
assay and its spectrum of applicability in the management of
arthritic patients will be determined by forthcoming larger case
studies.
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